Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2018 1
2021 1
2024 2
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Toxicity of ocular medications.
Benjamin KW. Benjamin KW. Int Ophthalmol Clin. 1979 Spring;19(1):199-255. doi: 10.1097/00004397-197901910-00011. Int Ophthalmol Clin. 1979. PMID: 376469 Review. No abstract available.
Outcome measurements in epidermal necrolysis: a systematic review.
Libson K, Mehta N, Kirven R, Korman AM, Kaffenberger BH. Libson K, et al. Arch Dermatol Res. 2024 Jun 15;316(7):392. doi: 10.1007/s00403-024-03062-5. Arch Dermatol Res. 2024. PMID: 38878166 Free PMC article.
Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), grouped together under the terminology of epidermal necrolysis (EN), are a spectrum of life-threatening dermatologic conditions. ...Following PRISMA guidelines, we conducted a systematic review of prospect …
Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), grouped together under the terminology of epidermal necrolysis (E …
Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C, Monnet D, Kramkimel N, Tréluyer JM, Mouthon L, Brézin A, Dupin N, Valnet-Rabier MB, Chouchana L, Terrier B. Mettler C, et al. Ophthalmology. 2021 Dec;128(12):1748-1755. doi: 10.1016/j.ophtha.2021.05.008. Epub 2021 May 14. Ophthalmology. 2021. PMID: 34000304
PURPOSE: BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) significantly improved metastatic melanoma prognosis. Ocular adverse effects (OAEs) represent an uncommon but disabling toxicity of these drugs. ...Ocular adverse effects were classified according to …
PURPOSE: BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) significantly improved metastatic melanoma prognosis. Ocular adverse effec …
Ophthalmologic toxicities of antineoplastic agents in genitourinary cancers: Mechanisms, management, and clinical implications.
Mahadevan A, Yazdanpanah O, Patel V, Benjamin DJ, Kalebasty AR. Mahadevan A, et al. Curr Probl Cancer. 2025 Feb;54:101171. doi: 10.1016/j.currproblcancer.2024.101171. Epub 2024 Dec 20. Curr Probl Cancer. 2025. PMID: 39708456 Free article. Review.
For each category of antineoplastic therapy, we describe the epidemiology, management, and clinical presentation, of common ophthalmologic toxicities stemming from these agents. This review serves to augment awareness and recognition of possible ophthalmologic manifestatio …
For each category of antineoplastic therapy, we describe the epidemiology, management, and clinical presentation, of common ophthalmologic …
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM, Hwang CK, Kim BJ. Kolomeyer AM, et al. J Med Case Rep. 2018 Nov 16;12(1):349. doi: 10.1186/s13256-018-1822-9. J Med Case Rep. 2018. PMID: 30442199 Free PMC article. Review.
CASE PRESENTATION: A 75-year-old white man with B-cell chronic lymphocytic leukemia on ibrutinib therapy and without significant past ocular history presented 1 day after uncomplicated phacoemulsification with in-the-bag intraocular lens implantation with multiple, discret …
CASE PRESENTATION: A 75-year-old white man with B-cell chronic lymphocytic leukemia on ibrutinib therapy and without significant past ocu …